New drug SIBP-A18 enters human testing for Hard-to-Treat cancers
NCT ID NCT06985368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called SIBP-A18 in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug and are monitored for side effects and how the drug moves through the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLDN18.2 POSITIVE LATE STAGE GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a genetic marker guide future cancer therapies in taiwan?
- AI reads tumor slides: can computer scores predict who will do well?
- No more hospital trips? video nutrition counseling tested for cancer weight loss
- Simple senior health quiz may predict chemo dangers
- Engineered immune cells take on Hard-to-Treat cancers
- New Dual-Action drug targets Hard-to-Treat tumors